Obstet Gynecol Sci.  2023 Mar;66(2):100-106. 10.5468/ogs.22267.

Growth inhibition by fusidic acid in cervical, thyroid, and breast carcinoma cell lines

• Kim JY
• Jegal BS
• Koh AR
• Park KS
• Kim JB
• Bae J

• KMID: 2540479
• DOI: http://doi.org/10.5468/ogs.22267

Abstract

Objective
We investigated the effects of fusidic acid (FA) on human cervical, thyroid, and breast carcinoma cell lines to determine the potential usefulness of FA in cancer treatment.
Methods
Six cancer cell lines (cervical cancer: Caski, HeLa; thyroid cancer: 8505C, TPC1; and breast cancer: MCF-7, MDA-MB-231) were treated with FA. Furthermore the changes in cell growth, cell cycle duration, and extent of apoptosis were analyzed.
Results
After FA treatment, the cancer cells showed a decrease in growth rate. In the cell death assay, the cell populations were similar in each cell type after treatment with FA, indicating that growth inhibition by FA was not related to the induction of apoptosis. FA induced cell cycle arrest at a dose that inhibited growth rate, which varied in different cell types. G0/G1 phase arrest occurs in breast cancer, S phase arrest in 8505C thyroid cancer, and G2/M phase arrest in cervical cancer. These results indicate that FA reduces growth rates by inducing cell cycle arrest.
Conclusion
FA treatment can interfere with cell proliferation by inducing cell cycle arrest in human cervical, thyroid, and breast carcinoma cell lines. Thus, FA can be useful in treating human cervical, thyroid, and breast carcinomas.

Keyword

Fusidic acid; Cervical cancer; Thyroid cancer; Breast cancer

Figure

• 

  Fig. 1 Effect of FA on six cancer cell lines (breast cancer cell lines: MCF-7, MDA-MB-231; thyroid cancer: 8505C, TPC1; cervical cancer: Caski, HeLa) were treated with FA at 10 μM, 100 μM, and 200 μM. CTL, control; FA, fusidic acid. *A significant inhibitory effect was shown at the concentraion of 100 μM and 200 μM in breast cancer cancer cell lines, 100 μM and 200 μM in thyroid cancer cell lines, and 200 μM in cervical cancer cell lines respectively.

• 

  Fig. 2 Cell death analysis was done after treatment of six cancer cell lines with FA at 100 μM and 200 μM through Annexin V and PI staining followed by flow cytometry. (A) breast cancer cells (MCF-7, MDA-MB-231), (B) thyroid cancer cells (8505C, TPC1), (C) cervical cancer cells (Caski, HeLa). CTL, control; FA, fusidic acid; FITC, fluorescein isothiocyanate; PI, propidium iodide.

• 

  Fig. 3 Six cancer cells were treated with the indicated amounts of FA at 100 μM and 200 μM for 72 hours and the percentages of cells at each stage of the cell cycle were analyzed by flow cytometry after staining the DNA with PI. (A) Breast cancer cells (MCF-7, MDA-MB-231), (B) thyroid cancer cells (8505C, TPC1), (C) cervical cancer cells (Caski, HeLa). CTL, control; FA, fusidic acid; PI, propidium iodide.

Reference

References

1. Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999–2017: Korea Central Cancer Registry. Obstet Gynecol Sci. 2021; 64:444–53.

2. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2019 [Internet]. Goyang: National Cancer Information Center;c2019. [cited 2022 Oct 27]. Available from: https://ncc.re.kr/cancerStatsView.ncc?bbsnum=578&searchKey=total&searchValue=&pageNum=1 .

3. Fernandes P. Fusidic acid: a bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections. Cold Spring Harb Perspect Med. 2016; 6:a025437.

4. Savelsbergh A, Rodnina MV, Wintermeyer W. Distinct functions of elongation factor G in ribosome recycling and translocation. RNA. 2009; 15:772–80.

5. Godtfredsen WO, Jahnsen S, Lorck H, Roholt K, Tybring L. Fusidic acid: a new antibiotic. Nature. 1962; 193:987.

6. Harvey CL, Knight SG, Sih CJ. On the mode of action of fusidic acid. Biochemistry. 1966; 5:3320–7.

7. Howden BP, Grayson ML. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis. 2006; 42:394–400.

8. Arigoni D, Vondaehne W, Godtfredsen WO, Marquet A, Melera A. The location of the ring C hydroxyl group in fusidic acid. Experientia. 1963; 19:521–2.

9. Yamaki H. Inhibition of protein synthesis by fusidic and helvolinic acids, steroidal antibiotics. J Antibiot (Tokyo). 1965; 18:228–32.

10. Koripella RK, Chen Y, Peisker K, Koh CS, Selmer M, Sanyal S. Mechanism of elongation factor-G-mediated fusidic acid resistance and fitness compensation in Staphylococcus aureus. J Biol Chem. 2012; 287:30257–67.

11. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, et al. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med. 2007; 43:1313–21.

12. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, et al. Taxanes: a new class of antitumor agents. Cancer Invest. 1995; 13:381–404.

13. White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. Mol Oncol. 2009; 3:402–8.

14. Thornes RD, Sheehan MV. “Fucidin” therapy in carcinoma of the breast. (Preliminary report). J Ir Med Assoc. 1966; 58:52–4.

15. New Zealand Medicines and Medical Devices Safety Authority. Fucidin patient information leaflet [Internet]. Wellington (NZ): New Zealand Medicines and Medical Devices Safety Authority;c2017. [cited 2022 Oct 27]. Available from: https://www.medsafe.govt.nz/consumers/cmi/f/Fucidin.pdf .